| Literature DB >> 35458630 |
Karolina Bernacka1, Katarzyna Bednarska1, Aneta Starzec1, Sylwester Mazurek2, Izabela Fecka1.
Abstract
Reactive oxygen and carbonyl species promote oxidative and carbonyl stress, and the development of diabetes, metabolic syndrome, cardiovascular diseases, and others. The traditional herb Cistus × incanus is known for its antioxidant properties; therefore, the current study aimed to assess how the chemical composition of a C. incanus water infusion corresponds with its antioxidative and antiglycative effects in vitro. The composition of infusions prepared from commercial products was analyzed with UHPLC-ESI-qTOF-MS. Total phenolics, flavonoids, and non-flavonoid polyphenols were determined. Antioxidant activity of infusions and selected polyphenols was investigated using DPPH, ABTS, and FRAP. Fluorometric measurements and methylglyoxal capture were performed to investigate the antiglycation activity. PCA and PLS-DA models were applied to explore the correlation between chemical and antioxidant results. The principal flavonoids in C. incanus were flavonols. In vitro tests revealed that a stronger antioxidant effect was demonstrated by plant material from Turkey rich in flavonoids, followed by Albania and Greece. Flavonols and ellagic acid displayed stronger antiradical and reducing power than EA-derived urolithins. Hyperoside was the most potent inhibitor of glycation. The results indicate that flavonoids are primarily responsible for rock rose antioxidant and antiglycation properties. PLS-DA modeling can be used to identify the origin of plant material with sensitivity and specificity exceeding 86%.Entities:
Keywords: Cistus × incanus; PCA; PLS-DA; antioxidants; flavonols; glycation inhibitors; methylglyoxal trapping; polyphenols; urolithins
Mesh:
Substances:
Year: 2022 PMID: 35458630 PMCID: PMC9032239 DOI: 10.3390/molecules27082432
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Total phenolics (TPC), flavonoids (TFC), and non-flavonoid polyphenols (TPC-TF) in C. incanus water infusions.
| Sample | TPC | TFC | TPC-TFC a | TPC:TFC | |
|---|---|---|---|---|---|
| GAE | ME | ||||
| All | Mean | 54.69 ± 8.23 | 31.73 ± 8.55 | 23.14 ± 9.73 | 1.8 ± 0.5 |
| Median | 56.05 | 30.22 | 24.4 | 1.8 | |
| Minimum | 35.39 | 16.7 | 1.33 | 1 | |
| Maximum | 73.09 | 58.68 | 46.18 | 3.1 | |
| Albania | Mean | 55.3 ± 6.97 | 28.92 ± 6.32 | 26.37 ± 6.99 | 2 ± 0.3 |
| Median | 55.03 | 27.07 | 27.97 | 2 | |
| Minimum | 43.24 | 21.44 | 12.7 | 1.3 | |
| Maximum | 73.09 | 41.32 | 39.44 | 2.6 | |
| Greece | Mean | 53.57 ± 4.95 | 24.47 ± 2.19 | 29.1 ± 7.08 | 2.2 ± 0.4 |
| Median | 52.72 | 24.52 | 28.2 | 2.2 | |
| Minimum | 47.74 | 21.7 | 20.6 | 1.8 | |
| Maximum | 61.08 | 27.14 | 39.38 | 2.8 | |
| Turkey | Mean | 52.92 ± 9.13 | 35.96 ± 9.23 | 16.96 ± 8.92 | 1.5 ± 0.4 |
| Median | 53.42 | 33.98 | 17.49 | 1.5 | |
| Minimum | 35.39 | 16.7 | 1.33 | 1 | |
| Maximum | 69.41 | 58.68 | 36.77 | 3.1 |
n, number of infusions; a, difference between TPC and TFC values.
UHPLC-ESI-MS data of C. incanus infusion components in negative ion mode.
| No. | Rt [min] | [M − H]− | MS/MS | Identification | Reference |
|---|---|---|---|---|---|
| 1 | 5.52 | 781.0581 | Punicalin | [ | |
| 2 | 5.90 | 781.0583 | [ | ||
| 3 | 13.57 | 1083.0631/541.0264 a | 781, 601, 301 | Punicalagin | [ |
| 4 | 15.90 | 1083.0637/541.0264 a | 781, 601, 451, 301 | [ | |
| 5 | 16.97 | 1085.0769/542.026 a | 301 | Terflavin A | [ |
| 6 | 18.08 | 1251.0706/625.0285 a | 301 | Cistusin | [ |
| 7 | 19.05 | 300.9841 | 257, 229 | Ellagic acid | [ |
| 8 | 19.92 | 631.098 | 316/317 b | Myricetin- | [ |
| 9 | 20.44 | 479.0854 | 316/317 b | Myricetin-3- | [ |
| 10 | 20.70 | 479.0861 | 316/317 b | Myricetin-3- | [ |
| 11 | 20.00 | 493.1377 | 313, 179 | Dimethyl-kaempferol- | [ |
| 12 | 21.82 | 449.0751 | 316/317 b | Myricetin-3- | [ |
| 13 | 22.09 | 463.091 | 316/317 b | Myricitrin (myricetin-3- | [ |
| 14 | 22.40 | 463.0906 | 300/301 b | Hyperoside (quercetin-3- | [ |
| 15 | 22.71 | 463.091 | 300/301 b | Isoquercitrin (quercetin-3- | [ |
| 16 | 23.74 | 433.0798 | 300/301 b | Quercetin-3- | [ |
| 17 | 24.05 | 433.0801 | 300/301 b | Quercetin-3- | [ |
| 18 | 24.39 | 447.0949 | 300/301 b | Quercitrin(quercetin-3- | [ |
| 19 | 28.77 | 609.1293 | 301 | Quercetin- | [ |
| 20 | 30.27 | 593.1348 | 285 | Tiliroside (6″- | [ |
a, [M − 2H]2−; b, [Y0 − H]−•/[Y0]− (radical aglycone ion/aglycone ion).
Antioxidant activity of C. incanus water infusions.
| Sample Origin | DPPH | ABTS | FRAP | ||||
|---|---|---|---|---|---|---|---|
| Inhibition a [%] | GAE | Inhibition a [%] | GAE | Fe(II) | GAE | ||
| All | Mean | 28.12 ± 5.63 | 24.98 ± 5.68 | 27.36 ± 5.92 | 1.39 ± 0.43 | 134.21 ± 42.72 | 29.73 ± 9.76 |
| Median | 28.05 | 24.73 | 28.33 | 1.35 | 128.18 | 28.33 | |
| Minimum | 13.29 | 11.38 | 7.31 | 0.54 | 69.29 | 11.39 | |
| Maximum | 42.65 | 43.37 | 40.31 | 2.79 | 314.28 | 71.89 | |
| Albania | Mean | 25.94 ± 6.16 | 22.54 ± 5.42 | 25.01 ± 6.66 | 1.33 ± 0.47 | 115.39 ± 28.73 | 25.12 ± 6.94 |
| Median | 27.1 | 23.88 | 26.25 | 1.29 | 110.39 | 24.47 | |
| Minimum | 13.29 | 11.38 | 7.31 | 0.54 | 69.29 | 11.39 | |
| Maximum | 35.45 | 30.35 | 36.43 | 2.58 | 168.53 | 37.36 | |
| Greece | Mean | 24.09 ± 1.4 | 20.63 ± 1.19 | 21.83 ± 1.68 | 1.37 ± 0.49 | 107.72 ± 11 | 23.80 ± 3.08 |
| Median | 24.13 | 20.65 | 22.19 | 1.11 | 106.7 | 23.65 | |
| Minimum | 22.09 | 18.91 | 19.18 | 1.05 | 93.26 | 19.61 | |
| Maximum | 26.03 | 22.28 | 23.77 | 2.21 | 124.2 | 28.3 | |
| Turkey | Mean | 30.90 ± 5.31 | 27.02 ± 4.95 | 29.41 ± 6.02 | 1.47 ± 0.45 | 155.22 ± 47.74 | 34.53 ± 10.87 |
| Median | 29.56 | 25.73 | 30.06 | 1.43 | 146.04 | 32.37 | |
| Minimum | 20.35 | 17.42 | 17.56 | 0.84 | 90.92 | 20.15 | |
| Maximum | 42.65 | 38.09 | 40.31 | 2.79 | 314.28 | 71.89 | |
n, number of infusions; a, calculated for samples diluted 1:5.
Antioxidant effect of selected flavonols (aglycones, glycosides), and depsides (ellagitannin metabolites).
| Sample | DPPH | ABTS | FRAP | |||
|---|---|---|---|---|---|---|
| IC50 | Inhibition a
| IC50 | Inhibition a
| Fe(II) b | GAE b | |
| Kaempferol | 6.52 ± 0.31 | 41.17 ± 1.88 | 8.04 ± 0.14 | 33.6 ± 0.24 | 45.99 ± 0.2 | 6.69 ± 0.06 |
| Quercetin | 3.53 ± 0.51 | 63.06 ± 4.15 | 4.30 ± 0.66 | 54.24 ± 8.21 | 116.59 ± 4.26 | 24.44 ± 0.73 |
| Myricetin | 3.06 ± 0.1 | 86.13 ± 2.06 | 3.15 ± 0.18 | 79.8 ± 6.07 | 64.67 ± 0.76 | 12.2 ± 0.22 |
| Hyperoside | 3.91 ± 0.2 | 57.26 ± 2.04 | 7.97 ± 1.1 | 32.28 ± 5.13 | 49.76 ± 1.7 | 4.84 ± 0.29 |
| Myricitrin | 3.31 ± 0.08 | 78.48 ± 1.96 | 3.92 ± 0.21 | 66 ± 2.3 | 62.72 ± 1.62 | 11.63 ± 0.48 |
| Ellagic acid | 2.35 ± 0.07 | 91.27 ± 0.13 | 3.82 ± 0.13 | 59.66 ± 4.18 | 100.99 ± 3.69 | 22.92 ± 1.09 |
| Urolithin A | 16.15 ± 0.63 | 18.11 ± 0.61 | 5.47 ± 0.56 | 49.48 ± 6.11 | 43.13 ± 2.65 | 5.85 ± 0.78 |
| Urolithin B | <0 | <0 | 27.72 ± 3.54 | 7.63 ± 2.07 | 16.41 ± 0.38 | <0 |
| Urolithin C | 4.77 ± 0.03 | 54.54 ± 0.43 | 6.28 ± 0.64 | 42.3 ± 4.15 | 59.73 ± 2.04 | 10.75 ± 0.6 |
Values averaged from 3 measurements; a, calculates for a final concentration of 5 µM; b, calculated for a final concentration of 9 µM.
Figure 1Antiglycation activity after seven days of incubation of BSA with MGO (0.5 mM) and the examined compound (1.5 mM) expressed as % inhibition of MGO-mediated AGE formation. The results are representative of three experiments performed in triplicate ± SD. Values not sharing a common letter are significantly different at p < 0.05 by Tukey’s multiple comparisons test. Abbreviations: AG, aminoguanidine; MET, metformin; K, kaempferol; Q, quercetin; M, myricetin; H, hyperoside; MR, myricitrin.
Reaction products of methylglyoxal with flavonols (standard or present in the water infusion) formed after 1 h of incubation in phosphate buffer solution pH 7.4 at 37 °C.
| Flavonol or Product | Source | Rt | [M − H]− | Adduct or Precursor |
|---|---|---|---|---|
|
| S | 32.39 | 285.0411 | |
| 25.67 | 429.0818 | di-MGO-Kaempferol | ||
| 25.77 | 429.0821 | di-MGO-Kaempferol | ||
| 27.98 | 357.0616 | mono-MGO-Kaempferol | ||
| 28.63 | 357.0611 | mono-MGO-Kaempferol | ||
|
| S | 28.90 | 301.0354 | |
| 23.99 | 445.0788 | di-MGO-Quercetin | ||
| 25.62 | 373.0563 | mono-MGO-Quercetin | ||
| 25.78 | 373.0564 | mono-MGO-Quercetin | ||
|
| S | - | - | - |
|
| S | 22.40 | 463.0886 | |
| 19.00 | 607.1288 | di-MGO -Hyperoside | ||
| 19.65 | 535.1089 | mono-MGO-Hyperoside | ||
| 19.88 | 535.1091 | mono-MGO-Hyperoside | ||
| 20.48 | 535.1094 | mono-MGO-Hyperoside | ||
| 20.70 | 535.1092 | mono-MGO-Hyperoside | ||
|
| S | 22.09 | 463.0902 | |
| 19.91 | 535.1097 | mono-MGO-Myricitrin | ||
| 20.24 | 535.1108 | mono-MGO-Myricitrin | ||
| 20.31 | 535.1105 | mono-MGO-Myricitrin | ||
| 20.48 | 535.1101 | mono-MGO-Myricitrin | ||
| 20.59 | 535.1101 | mono-MGO-Myricitrin | ||
|
| Inf. | 22.09 | 463.0909 | Myricitrin |
| 22.40 | 463.0906 | Hyperoside | ||
| 19.67 | 535.1116 | mono-MGO-Hyperoside | ||
| 19.90 | 535.1134 | mono-MGO-Myricitrin | ||
| 20.24 | 535.1135 | mono-MGO-Myricitrin | ||
| 20.31 | 535.1137 | mono-MGO-Myricitrin | ||
|
| Inf. | 22.09 | 463.0909 | Myricitrin |
| 22.40 | 463.0906 | Hyperoside | ||
| 19.65 | 535.1115 | mono-MGO-Hyperoside | ||
| 19.88 | 535.1117 | mono-MGO-Hyperoside | ||
| 20.24 | 535.1123 | mono-MGO-Myricitrin |
S, reference standard; Inf., infusion.
Correlation between chemical composition and antioxidant effect (as heatmap).
| Sample | Method | Unit | TPC | TFC | TPC-TFC a |
|---|---|---|---|---|---|
| All | TPC | GAE [mg/g] | - | ||
| TFC | ME [mg/g] | 0.28 | - | ||
| TPC-TFC | [mg/g] | 0.6 | −0.6 | - | |
| DPPH | Inhibition [%] | 0.19 | 0.69 | −0.41 | |
| ABTS | Inhibition [%] | 0.25 | 0.49 | −0.2 | |
| FRAP | Fe(II) [mM/g] | 0.25 | 0.72 | −0.39 | |
| Albania | TPC | GAE [mg/g] | - | ||
| TFC | ME [mg/g] | 0.39 | - | ||
| TPC-TFC | [mg/g] | 0.61 | −0.49 | - | |
| DPPH | Inhibition [%] | 0.54 | 0.81 | −0.19 | |
| ABTS | Inhibition [%] | 0.48 | 0.45 | 0.08 | |
| FRAP | Fe(II) [mM/g] | 0.29 | 0.88 | −0.49 | |
| Turkey | TPC | GAE [mg/g] | - | ||
| TFC | ME [mg/g] | 0.46 | - | ||
| TPC-TFC | [mg/g] | 0.54 | −0.5 | - | |
| DPPH | Inhibition [%] | 0.24 | 0.51 | −0.26 | |
| ABTS | Inhibition [%] | 0.23 | 0.53 | −0.27 | |
| FRAP | Fe(II) [mM/g] | 0.4 | 0.71 | −0.29 |
n, number of infusions; a, difference between TPC and TFC values.
Figure 2PCA (left) and PLS−DA (right) score plots for C. incanus parameters modeling (A, Albanian; G, Greek, T, Turkish plant material).
Figure 3PLS−DA: score plots for C. incanus parameters with the values of the TPC:TFC ratio (A, Albanian; G, Greek, T, Turkish plant material).